Nuclear RNA-binding protein p54 nrb and its murine homolog NonO are known to be involved in a variety of nuclear processes including transcription and RNA processing. Melanoma inhibitory activity (MIA) has been shown to play an essential role in the progression of malignant melanoma and to influence melanomaassociated molecules and pathways in the early tumor formation steps. Interestingly, recent studies suggest that MIA is a regulator of p54 nrb . Here, we show that p54 nrb is strongly expressed and localized in the nucleus of both melanoma cell lines and melanoma tissue samples compared with normal human melanocytes or normal skin, respectively. Furthermore, all tested melanoma cell lines revealed strong p54 nrb promoter activity. Treatment with MIAspecific small interfering RNAs showed an influence of MIA on p54 nrb expression on both messenger RNA (mRNA) and protein level. Knockdown of p54 nrb protein in melanoma cell lines led to reduced proliferation rates and to a strong decrease in their migratory potential. In addition, attachment to laminin and poly-Llysine was significantly increased. We could identify Connexin-43 (Cx-43) as a downstream target molecule of p54 nrb as knockdown of p54 nrb resulted in enhanced Cx-43 mRNA and protein levels. As a confirmation of these findings, melanoma cell lines showed very low Cx-43 expression levels compared with melanocytes. Our results demonstrate that p54 nrb is highly expressed in malignant melanoma and, as a MIA target molecule, it seems to be involved in the development and progression of malignant melanoma.
Nuclear RNA-binding protein p54 nrb and its murine homolog NonO are known to be involved in a variety of nuclear processes including transcription and RNA processing. Melanoma inhibitory activity (MIA) has been shown to play an essential role in the progression of malignant melanoma and to influence melanomaassociated molecules and pathways in the early tumor formation steps. Interestingly, recent studies suggest that MIA is a regulator of p54 nrb . Here, we show that p54 nrb is strongly expressed and localized in the nucleus of both melanoma cell lines and melanoma tissue samples compared with normal human melanocytes or normal skin, respectively. Furthermore, all tested melanoma cell lines revealed strong p54 nrb promoter activity. Treatment with MIAspecific small interfering RNAs showed an influence of MIA on p54 nrb expression on both messenger RNA (mRNA) and protein level. Knockdown of p54 nrb protein in melanoma cell lines led to reduced proliferation rates and to a strong decrease in their migratory potential. In addition, attachment to laminin and poly-Llysine was significantly increased. We could identify Connexin-43 (Cx-43) as a downstream target molecule of p54 nrb as knockdown of p54 nrb resulted in enhanced Cx-43 mRNA and protein levels. As a confirmation of these findings, melanoma cell lines showed very low Cx-43 expression levels compared with melanocytes. Our results demonstrate that p54 nrb is highly expressed in malignant melanoma and, as a MIA target molecule, it seems to be involved in the development and progression of malignant melanoma.
Introduction
According to the World Health Organization, malignant melanoma is the most dangerous variant of skin cancer. Patients can be cured by early surgical excision of the non-metastatic primary tumor, whereas prognosis of patients suffering from metastatic melanoma is poor. One of the key molecules regulating melanoma progression is the protein melanoma inhibitory activity (MIA) which is strongly expressed in malignant melanoma but absent in normal human melanocytes (1) . Several studies suggest an important role for MIA also in the early tumor formation steps by regulating melanoma-related pathways and molecules (1) . Recent investigations in mesenchymal stem cells hinted to paraspeckle protein p54 nrb as one of the MIA-regulated proteins (2) .
The nuclear p54 nrb protein is a RNA-binding molecule of 54 kDa containing two RNA recognition motifs. It was first purified from HeLa cells in 1993 (3) . p54 nrb is able to bind double-stranded DNA, single-stranded DNA and RNA, allowing the conclusion that p54 nrb has dual roles in transcription and splicing (4) . Moreover, it retains Ato-I-hyperedited messenger RNA (mRNA) in the nucleus and therefore influences gene expression and differentiation of stem cells (5) . p54 nrb was found to play an important role during chondrogenesis by directly interacting with the transcription factor Sox9 in paraspeckles. This results in the enhanced transcriptional activation of the collagen type II a1 (Col2a1) promoter through Sox9 (6) .
Paraspeckles are nucleoplasmic compartments containing mainly four different RNA-binding proteins: paraspeckle protein 1, paraspeckle protein 2, polypyrimidine tract-binding protein-associated splicing factor and p54 nrb [also called NonO (Non-POU-domain-containing octamerbinding protein)]. All human cell types contain 10-20 paraspeckles (5, 7, 8) . Non-coding RNAs of a certain length are arranged in close contact to paraspeckle proteins, especially the nuclear-enriched autosomal transcript non-coding RNA 1 (5, 8) . These RNA-protein interactions are important for maintaining the structure of paraspeckle compartiments (5, 8) . Within the paraspeckles, p54 nrb can either form heterodimers with protein-associated splicing factor or act as a monomer (9) .
Recent studies in chondrocytes suggest that MIA is able to regulate the transcription of p54 nrb (2) and that p54 nrb plays an important role in modification mRNA expression (6) . We performed this study to reveal whether there is also a correlation between MIA and p54 nrb in malignant melanoma. Therefore, we analyzed the expression and regulation of p54 nrb in melanoma cell lines and melanoma tissue samples and examined the functional role of p54 nrb for the development and progression of malignant melanoma.
Materials and methods

Cell lines and culture conditions
The melanoma cell lines Mel Ei, Mel Wei, Mel Ho, Mel Juso (derived from primary cutaneous melanomas), Mel Ju, SK-MEL-3, SK-MEL-28, Mel Im and HMB2 (derived from metastases of malignant melanomas) have been described previously (10, 11) . The MIA-deficient HMB2 cell clones HMB2-MIA 5 and HMB2-MIA 8 have been generated through antisense technology and described previously in detail (12) . As a mock control, b-galactosidase-expressing HMB2 lacZ cells were used. For tissue culture, cells were maintained in Dulbecco's modified Eagle's medium (DMEM) (PAA; Pasching, Austria) supplemented with penicillin (400 U/ml), streptomycin (50 lg/ml) (both PAA) and 10% fetal calf serum (Sigma, Deisenhofen, Germany). Stable-transfected HMB2 cell clones were cultured in selection medium, containing 50 lg/ml G418 (Sigma-Aldrich, Taufkirchen, Germany). Normal human epidermal melanocytes (NHEM) derived from normal skin of different donors were cultivated in melanocyte growth medium (Promocell, Heidelberg, Germany). All cells were incubated in humidified atmosphere containing 8% CO 2 at 37°C.
Tissue samples
Snap-frozen tissue samples of primary tumors (TB62, TB71, TB72, TB97) and metastatic melanomas (TB12, TB43, TB100: all skin metastasis; TB50: lung metastasis; TB69: brain metastasis) were obtained from the tissue collection of the Institute of Pathology, University of Regensburg, Germany. Sampling and handling of human tissue material was carried out in accordance with the ethical principle of the Declaration of Helsinki.
RNA isolation and reverse transcription
Total cellular RNA was isolated from cultured cells using the e.Z.N.A.Ò MicroEluteÒ Total RNA Kit (Omega Bio-Tek, Norcross, GA) as described by the manufacturers. Complementary DNA was generated by reverse transcription. The reverse transcription reaction was performed in 20 lL reaction volume containing 2 lL of total cellular RNA, 4 lL of Â5 first-strand buffer, 2 lL of 0.1 M dithiothreitol (both Invitrogen, Karlsruhe, Germany), 1 lL of dN6 primer (10 mM) (Roche Applied Science, Mannheim, Germany), 1 lL of dNTPs (10 mM) (Amersham pharmacia biotech, Pittsburgh, PA, USA) and diethylpyrocarbonate water. The reaction mix was incubated for 10 min at 70°C. Then, 1 lL of Superscript II reverse transcriptase (Invitrogen) was added, and RNA was transcribed for 1 h at 37°C. Subsequently, reverse transcriptase was inactivated at 70°C for 10 min, and RNA was degraded by digestion with 1 ll RNase A (10 mg/ml) (Roche, Mannheim, Germany) at 37°C for 30 min. The quality of complementary DNA was controlled and normalized Abbreviations: AEC, 3-amino-9-ethylcarbazole; DEPC, diethylpyrocarbonate; DMEM, Dulbecco's modified Eagle's medium; dsDNA, double-stranded DNA; ECM, extracellular matrix; MIA, melanoma inhibitory activity; mRNA, messenger RNA; NHEM, normal human epidermal melanocytes; PARP, poly ADP-ribose polymerase; PBS, phosphate-buffered saline; POD, peroxidase; qRT-PCR, quantitative real-time polymerase chain reaction; RIPA, radioimmunoprecipitation; siMIA, cells treated with specific MIA siRNA; siRNAs, small interfering RNAs; ssDNA, single-stranded DNA; XTT, 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide. 
Analysis of expression by qRT-PCR
qRT-PCR analysis for p54 nrb and Cx-43 was performed on a LightCycler system (Roche). A volume of 2 ll complementary DNA template, 0.5 ll (20 mM) of forward and reverse primers (b-act forward: 5#-CTACGTCGCCCTG-GACTTCGAGC-3# and b-act reverse: 5#-GATGGAGCCGCCGATCCA-CACGG-3#; p54 nrb forward: 5#-TTCCTCCCGACATCACTGAG-3# and p54 nrb reverse: 5#-ATCCACAATGACTACAGCCCT-3#; Cx-43 forward: 5#-AGGG-GGAAGGCGTGAGGAA-3# and Cx-43 reverse: 5#-GCCTGGGCACCACT-CTTTTG-3#) and 10 ll of SYBR Premix Ex Taq (TaKaRa, Otsu, Japan) were combined to a total volume of 20 ll. PCR primers were obtained from Sigma. The PCR program used was as follows: 30 s at 95°C (initial denaturation); 20°C/s temperature transition rate up to 95°C for 15 s, 3 s at 68°C, 5 s at 72°C, 86°C acquisition mode single and repeated for 40 times (amplification). Annealing and acquisition temperatures were optimized for each primer set. The PCR product was evaluated by melting-curve analysis according to the manufacturer's instructions and by agarose gel electrophoresis. Each analysis was performed at least in triplicate. The expression ratios of the analyzed genes were calculated using an internal control standard curve of b-actin levels.
siRNA transfection
The siRNAs against p54 nrb (Hs_NONO_6, sense strand: 5#-GUGUUUGAUUU-GUCUCAUATT-3# and, antisense strand: 5#-UAUGAGACAAAUCAAACA-CAG-3#), Cx-43 (sense strand: 5#-ATGCTTAGAGTGGACTATTAA-3# and antisense strand: 5#-TTAATAGTCCACTCTAAGCAT-3#) and control siRNA (sense strand: 5#-UUCUCCGAACGUGUCACGUdTdT-3# and, antisense strand: 5#-ACGUGACACGUUCGGAGAAdTdT-3#) were synthesized by Qiagen (Hilden, Germany). Cells of the melanoma cell lines Mel Im and Mel Ei were grown to 70-80% confluence in culture dishes and harvested in the proliferative growth phase for transfection. Cells were transfected in six-well culture plates with the HiPerFect Transfection Reagent (Qiagen), according to the manufacturer's protocol. At 3 and 4 days after transfection, cells were harvested for RNA and protein isolation.
Immunohistochemical staining
Paraffin sections of healthy skin, nevi, primary tumors and metastases were screened for p54 nrb protein expression by immunohistochemistry. The tissues were fixed and subsequently incubated with specific p54 nrb antibody (1:50) (BD Biosciences, Bedford, MA) overnight at 4°C, with the secondary antibody (biotin-labeled anti-mouse; DAKO, Hamburg, Germany) for 30 min at room temperature and then with streptavidin-peroxidase (DAKO) for 30 min. Antibody binding was visualized using 3-amino-9-ethylcarbazole solution (DAKO). Finally, the tissues were counterstained with hemalaun solution (DAKO). Western blot analysis About 3 Â 10 6 cells were lysed in 200 ll radioimmunoprecipitation buffer (Roche) and incubated for 15 min at 4°C. Insoluble fragments were removed by centrifugation at 13 000 r.p.m. for 10 min at 4°C. The supernatant of the lysate was immediately shock frozen and stored at À80°C. 10-40 lg radioimmunoprecipitation lysate of each sample were loaded and separated on 12.75% sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels and subsequently blotted onto a polyvinylidene difluoride membrane (35 min, 15 V). After blocking for 1 h (anti-p54 
Immunofluorescence assays
Plasmid constructs
To analyze the human p54 nrb promoter in luciferase assays, a human genomic region of the p54 nrb gene was amplified by PCR with specific primer pairs (p54 nrb promoter forward: 5#-GACC/TCGAGGCGCGATCTCCACTCATTG-CAG-3# and p54 nrb promoter reverse: 5#-GACGAT/ATCTTCGCCCTAGCC-TCTTCCTTCG-3#) and cloned into pGL4. 10 [luc2] luciferase expression vector (Promega Corp., Madison, WI). The following promoter construct was generated: hp54nrb-8436/-6833 relative to start of translation. vector as a control), using the Lipofectamine plus method (Invitrogen) according to the manufacturer's instruction. Cells were lysed 24 h after transfection and luciferase activity in the lysate was quantified with a luminometer using Promega dual-luciferase assay reagent (Promega). Transfection efficiency was normalized according to renilla luciferase activity by cotransfecting 0.1 lg of the plasmid pRL-TK (Promega). All transfection experiments were repeated at least three times.
Cell proliferation assay Cellular proliferation was determined using the Cell Proliferation Kit II (Roche) according to the supplier's instructions. Cells were seeded as monolayer cultures in. Hundred milliliter cultivation medium (see above) without phenol red in a 96-well plate (Corning Inc., Lowell, MA) at a density of 5 Â 10 2 and 1 Â 10 3 cells per well and incubated in humidified atmosphere containing 8% CO 2 at 37°C for 4 days. Every day of incubation, 50 ll of 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide labeling and electron-coupling reagent (Roche) was added to the respective well and plates were incubated at 37°C. Absorbance was measured after 2 and 4 h of incubation at 450 nm against a reference wavelength at 650 nm using a microplate reader (Molecular Devices, E max precision microplate reader). Experiments were performed in triplicates and repeated at least twice. To assess the effect of siRNA transfection on cell viability, living cells were counted after fifth day of transfection.
Attachment assay
Cellular attachment to the extracellular matrix proteins fibronectin, laminin and poly-L-lysine was tested using coated 96-well plates (BD Biosciences). About 15 000 cells per well were placed in phenol red-free DMEM (PAA). After 20 min of incubation in fibronectin-and poly-L-lysine-coated wells, the remaining cells in the supernatant were counted. Supernatant of laminincoated wells was collected after 60 min.
Migration assay
Migration was assessed in Boyden chambers containing polycarbonate filters with an 8 lm pore size (NeuroProbe, Gaithersburg, MD) coated with gelatin. The lower compartment was filled with fibroblast-conditioned medium used as a chemoattractant and the filter was placed above. Transfected Mel Im and Mel Ei cells were harvested by trypsinization and resuspended in DMEM without fetal calf serum (PAA). Afterward, 800 ll of the cell suspension was placed in the upper compartment of the Boyden chambers at a density of 2 Â 10 5 cells/ml. After incubation at 37°C for 4 h, filters were removed and cells were fixed, stained and counted. Experiments were performed in triplicates and repeated at least twice.
Statistical analysis
The mean and standard deviation values were calculated from independent experiments, and the graphs were constructed with the GraphPad Prism software. Statistical significance between two groups was determined by using the Student's t-test. Software used was GraphPad Prism 4. Statistical significance p54 nrb expression in malignant melanoma was analyzed on data from at least three independent experiments. A P-value , 0.05 was considered statistically significant (ns: not significant, Ã P , 0.05).
Results
p54 nrb is highly expressed in malignant melanoma
Initially, p54 nrb expression was determined in melanoma cell lines using qRT-PCR analysis ( Figure 1A ) and western blotting technique ( Figure 1B ). We could demonstrate that p54 nrb expression was strongly induced in the melanoma cell lines Mel Juso, Mel Wei, Mel Ei, Mel Ho, Mel Im, SK-MEL-3, SK-MEL-28 and HMB2 compared with NHEM. To further address p54 nrb expression, we also analyzed its expression in melanoma tissues of primary tumors as well as skin, lung and brain metastases. Compared with melanocytes, p54 nrb expression is higher in all tissues ( Figure 1A ). To assess p54 nrb expression in situ, we performed immunohistochemical staining of p54 nrb in healthy skin, nevus, primary tumor and metastasis. Representative immunohistochemical sections are presented in Figure 1C . Here, lack of expression in melanocytes of healthy skin was confirmed, whereas melanoma cells of primary melanoma and metastasis revealed strong nuclear expression of p54 nrb . In nevus, tissue expression was heterogenous. Negative, positive and strong positive nevi could be distinguished.
In order to visualize the expression as well as the location of p54 nrb in vivo, we performed immunofluorescence staining of p54 nrb in the previously mentioned melanoma cell lines Mel Juso, Mel Ei, Mel Im, SK-MEL-28 and HMB2 in comparison with NHEM. In each case, p54 nrb showed a distinct nuclear staining and strong expression in melanoma ( Figure 1D ). In summary, we could show that p54 nrb is highly expressed in all melanoma cell lines and is localized in the nucleus.
To analyze whether the induction of p54 nrb expression was due to promoter regulation, we subcloned 1604 bp of the promoter region of p54 nrb into a luciferase reporter gene plasmid. Luciferase measurement after transient transfection of the construct into melanoma cell lines revealed strong activity ( Figure 1E ), suggesting that induction of p54 nrb is due to transcriptional regulation.
Regulation of p54 nrb expression
Since we could previously show a regulation of p54 nrb via MIA expression in chondrocytic differentiation (2), we analyzed in the next step, the hierarchy of regulation between MIA and p54 nrb in melanoma. The efficiency of MIA and p54 nrb knockdown by specific Figure 2B, I ). In contrast, p54 nrb mRNA expression was significantly reduced in cells treated with MIA-specific siRNA ( Figure 2B , II). Depletion of p54 nrb due to reduced MIA expression could also be confirmed on protein levels ( Figure 2C ). To further confirm the regulation of p54 nrb by MIA, we used MIA-negative cell clones of the cell line HMB2, which were generated by stable transfection of a MIA antisense construct (12, 13) . Compared with the control, cell lines HMB2 and HMB2 lacZ, MIA-negative cell clones showed almost complete loss of p54 nrb protein expression shown by western blot analysis ( Figure 2D ). According to these results, the activity of the p54 nrb promoter reporter construct was significantly reduced in the MIA-negative cell clones ( Figure 2E ).
Target genes of p54 nrb
Since it is already known that p54 nrb represses translation of the Connexin-43 (Cx-43) protein during pregnancy (14), we analyzed whether Cx-43 is also a target gene of p54 nrb in malignant melanoma.
In agreement with high p54 nrb expression levels in malignant melanoma ( Figure 1A and B), Cx-43 expression is reduced in melanoma cell lines compared with melanocytes (NHEM) as determined by qRT-PCR ( Figure 3A) . Downregulation of p54 nrb by siRNA technique in Mel Im cells resulted in significantly induced Cx-43 expression after 3 and 4 days compared with cells treated with control siRNA ( Figure 3B ). To confirm the effect of p54 nrb on Cx-43 protein expression, Mel Im cells were transfected with specific p54 nrb siRNA and western blots were performed. At day four, expression of Cx-43 protein is 2.4-fold higher in cells in which p54 nrb was silenced compared with control ( Figure 3C ). Because of these findings, we subsequently performed immunofluorescence staining of p54 nrb and Cx-43 in the melanoma cell lines Mel Im and SK-MEL-28 in which p54 nrb was silenced. Representative pictures are shown in Figure 3D . We were able to show that the expression of Cx-43 is induced when p54 nrb expression was inhibited.
Functional role of p54 nrb in melanoma cells
In order to determine the role of p54 nrb in development and progression of malignant melanoma, we first analyzed the effect of p54 nrb on cell proliferation by 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide assay using specific p54 nrb siRNA. The melanoma cell line Mel Im showed significant longer relative doubling times when treated with specific p54 nrb siRNA, indicating a reduced proliferation rate compared with controls ( Figure 4A ). These results were confirmed by cell counting of siRNA-transfected cells. Fortyeight hours after transfection with p54 nrb siRNA, significant fewer cells were determined compared with cells treated with control siRNA or untreated at all (Figure 4B, I ). To assess whether these effects are due to apoptosis, we analyzed expression and cleavage of PARP protein. Four days after transfection, western blot analysis revealed an accumulation of cleaved PARP protein in sip54 nrb -treated cells (Figure 4B, II) . 
p54 nrb expression in malignant melanoma
Furthermore, Mel Im as well as Mel Ei cells in which p54 nrb expression was knocked down showed significantly increased attachment to the extracellular matrix protein laminin and the synthetic protein poly-L-lysine compared with cells treated with control siRNA. No significant differences were observed with regards to attachment to fibronectin ( Figure 4C ). In addition, treatment with p54 nrb siRNA resulted in a strong repression of migratory activity of the melanoma cells Mel Im and Mel Ei compared with completely untreated cells or cells transfected with control siRNA ( Figure 4D ).
Discussion
Several studies indicate that MIA is not only involved in melanoma progression and metastasis but also plays an important role in the early steps of tumor formation by influencing several melanoma-associated molecules (1) . Recent investigations in view of cartilage differentiation show that the paraspeckle protein p54 nrb is one of the molecules regulated by MIA (2) .
In our study, we investigate the expression and function of p54 nrb in malignant melanoma. We could show that p54 nrb is strongly expressed in melanoma cell lines compared with normal human melanocytes. However, not all cell lines revealed a clear correlation between mRNA expression and protein amount suggesting additional post-transcriptional mechanisms of regulation.
In healthy skin, no p54 nrb protein expression was detectable in melanocytes. In contrast, tissue samples of human primary and metastatic melanomas showed strong nuclear p54 nrb expression. Within human nevi, p54 nrb expression pattern was found to be very heterogenous. We detected p54 nrb negative and weakly positive nevi as well as nevi revealing strong nuclear p54 nrb staining. Because of these findings, we assume that initiation of p54 nrb expression occurs early during tumorigenesis.
Luciferase reporter gene assays revealed strong p54 nrb promoter activity in melanoma cell lines, compared with normal human melanocytes, suggesting that the initiation of p54 nrb expression in melanoma cells and tissue is regulated on transcriptional level.
We recently described a MIA-deficient HMB2 melanoma cell system. In the MIA-deficient cell clones, we detected several differentially regulated melanoma-associated molecules compared with the parental HMB2 cell line (12, 13) . In further analyses, we found p54 nrb strongly downregulated in the MIA-negative HMB2 cell clones (2) .
In this study, we could confirm that MIA regulates p54 nrb expression in melanoma cells, whereas, as expected, p54 nrb expression does not alter MIA expression. We previously could show that MIA is able to interact with components of the extracellular matrix and a4b1 and a5b1 integrins (15) (16) (17) . Thereby, MIA is able to inhibit cell-matrix contacts, leading to detachment of the cell and progression of metastasis. We suppose that MIA-dependent regulation of p54 nrb expression is also mediated through binding to a4b1 and a5b1 integrin receptors and modulation of downstream signaling. The corresponding intracellular signaling pathways remain unclear so far and will be aim of further studies.
To clarify the role of p54 nrb for the development and progression of malignant melanoma, we analyzed the influence of p54 nrb on proliferation, survival and migration. Our data show that p54 nrb knockdown reduces the proliferative behavior of melanoma cells. Further, the number of living cells was reduced and the amount of apoptotic cells increased when p54 nrb was silenced. These findings confirm our hypothesis that p54 nrb plays an important role already in the early steps of tumor formation and that p54 nrb contributes to the insensitivity of melanoma cells against apoptosis. Even more, p54 nrb influences the migratory potential of melanoma cells. We could show that p54 nrb knockdown in melanoma cells significantly reduces migration. We, therefore, conclude that p54 nrb is involved in MIAmediated metastasis of melanoma cells. In addition, p54 nrb seems to influence the ability of melanoma cells to attach to components of the extracellular matrix. Knockdown of p54 nrb enhanced attachment of melanoma cells to laminin and poly-L-lysine, whereas no effect was seen with regards to fibronectin. These data also point to the impact of p54 nrb on the invasive capacity of melanoma cells. Further studies on other types of cancer support a correlation between p54 nrb expression and the invasive and progressive potential of tumor cells. In breast cancer, it was shown that loss of estrogen receptor hERa combined with loss or alteration of p54 nrb results in a more aggressive phenotype with poor prognosis (18) . Further, Barboro et al. (19) found a correlation between the presence of p54 nrb protein in transitional cell carcinoma and an increased mortality. These findings as well as our data show clearly an impact of p54 nrb on tumor progression and metastasis. We therefore assume that p54 nrb transcriptionally regulates cancer-associated genes by influencing mRNA modification processes.
As an interesting target molecule of p54 nrb , we could identify Connexin-43 (Cx-43). Connexins are components of gap junctions and involved in the maintenance of cell-cell contacts and signaling transduction in the healthy tissue. In our study, we observed that p54 nrb and Cx-43 are expressed in a contrary manner. We detected reduced Cx-43 expression levels in melanoma cells compared with NHEM. In addition, knockdown of p54 nrb led to an increase of Cx-43 expression, suggesting that p54 nrb inhibits cell-cell contacts and the maintenance of a normal tissue network via downregulation of Cx-43. These results correlate with previous findings that loss of Connexins lead to alterations in the activity of gap junctions, which has been implicated in several cancer types (20) . In the skin, intercellular communication through gap junctional channels regulates growth, differentiation and migration of keratinocytes as well as interactions between keratinocytes and melanocytes (21) . In particular, loss of Cx-43 expression causes alterations in the activity of gap junctions and therefore changes in cell-cell contact mechanisms (20) . These effects may essentially contribute to tumor progression.
Taken together, our data show that paraspeckle protein p54 nrb is a downstream target of MIA in malignant melanoma and is involved in several malignant processes including proliferation and invasion of melanoma cells. 
